Extensive hidradenitis suppurativa (HS) Hurly stage III disease treated with intravenous (IV) linezolid and meropenem with rapid remission.

Abstract

A 57-year-old woman with Hurley Stage 3 hidradenitis suppurativa (HS) and multiple co-morbidities is presented. She had failed multiple antibiotic therapies and etanercept. She had end stage renal disease and was on dialysis. Her HS was put into remission with one month of daily IV treatment with 1.2 grams linezolid and 1 gram of meropenem, administered daily through her dialysis shunt. Unfortunately, her disease flared again two weeks after the cessation of the IV treatment. Nevertheless, more conventional therapy was then able to maintain her disease at a level that was significantly improved over baseline prior to the IV treatment. This case highlights above all a primary etiology of HS is stimulus of immune system's over-reaction in HS to the bacterial microbiome. If antibiotics are administered to a patient with stage 3 HS powerful enough to wipe out the bacterial biome, the immune system having no target retreats, permanent scarring in its wake and retreats to a certain but hardly permanent normalcy.

• Authors: Noah Scheinfeld
• Journal: Dermatology online journal (Dermatol Online J) Vol. 21 Issue 2 (Feb 16 2015) ISSN: 1087-2108 [Electronic] United States
• PMID: 25756493 (Publication Type: Case Reports, Journal Article)

Chemical References

• Anti-Bacterial Agents
• Thienamycins
• Meropenem
• Linezolid

Topics

• Anti-Bacterial Agents (therapeutic use)
• Drug Therapy, Combination
• Female
• Hidradenitis Suppurativa (complications, drug therapy, immunology)
• Humans
• Infusions, Intravenous
• Kidney Failure, Chronic (complications)
• Linezolid (therapeutic use)
• Meropenem
• Middle Aged
• Obesity, Morbid (complications)
• Polycystic Kidney Diseases (complications)
• Remission Induction
• Thienamycins (therapeutic use)